Healthcare
Live Price
Offline$32.58
+1.46% today
1Y Change
-38.73%
Window
Jun 25, 2025 โ Jun 17, 2026
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CONMED Corporation (CNMD) is a Healthcare stock with a market cap of $1.13B and listed on NYSE. The stock last traded around $32.58 and down 38.7% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of -64.6%, a dividend yield of 1.1%. What stands out right now is revenue +5.2%, EPS -64.6%, free cash flow -2.0% with operating margin 11.2% and ROIC 5.1%. The dividend is present but secondary, with a yield around 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 20.4 and price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CNMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.2% vs +7.6% peer median
Operating Margin
Below sector median
+11.2% vs +19.4% peer median
P/E
Below sector median
20.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.2% and EPS is at -64.6%, with operating margin around 11.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.1%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.7% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +1.9% | +3.8% | -1.2% |
2026 Jan 28, 2026 | +8.3% | -3.6% | +3.2% | +18.6% |
2025 Nov 5, 2025 | +2.9% | -0.5% | -2.0% | -0.5% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNMD Max Drawdown
-42.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CNMD and SPY.
Company Overview
CONMED Corporation
NYSE
CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical equipment and medical devices for orthopedic and general surgery specialties. The company's orthopedic surgery segment provides products for soft tissue repair, powered resection instruments, and foot and ankle surgery systems. Its general surgery division offers advanced surgical and endoscopic technologies, including the AirSeal insufflation system for minimally invasive procedures, smoke evacuation products, electrosurgical generators, and specialized devices for gastroenterology and pulmonology procedures. CONMED serves healthcare professionals including surgeons and specialists in orthopedics, general surgery, gynecology, thoracic surgery, and related fields across approximately 100 countries. The company operates through sales subsidiaries and distribution networks in major markets including the United States, Europe, Asia Pacific, and other regions. CONMED caters to various healthcare settings ranging from ambulatory surgery centers and endoscopy suites to large hospital systems, focusing on delivering solutions that enhance surgical efficiency and patient outcomes in value-based care environments.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.